Merck & Co., Inc. $MRK Stock: Heritage Investors Management Corp Decreases Holdings

Heritage Investors Management Corp lowered its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 3.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 305,012 shares of the company’s stock after selling 11,580 shares during the quarter. Merck & Co., Inc. comprises about 1.3% of Heritage Investors Management Corp’s holdings, making the stock its 19th largest position. Heritage Investors Management Corp’s holdings in Merck & Co., Inc. were worth $44,321,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in MRK. Susquehanna Fundamental Investments LLC purchased a new stake in shares of Merck & Co., Inc. during the second quarter worth approximately $11,470,000. Russell Investments Group Ltd. grew its position in Merck & Co., Inc. by 2.0% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,578,024 shares of the company’s stock valued at $331,931,000 after buying an additional 51,393 shares during the last quarter. Cardinal Capital Management grew its position in Merck & Co., Inc. by 3.6% in the 3rd quarter. Cardinal Capital Management now owns 99,742 shares of the company’s stock valued at $14,578,000 after buying an additional 3,507 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in Merck & Co., Inc. by 12.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,073,176 shares of the company’s stock valued at $266,403,000 after buying an additional 227,589 shares during the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Merck & Co., Inc. by 7.0% in the 2nd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,184,340 shares of the company’s stock valued at $794,577,000 after buying an additional 402,011 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. Barclays upped their price objective on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a research report on Monday, October 26th. Cantor Fitzgerald boosted their price target on shares of Merck & Co., Inc. from $120.00 to $145.00 and gave the stock a “neutral” rating in a research note on Thursday, October 8th. Rothschild & Co Redburn boosted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a research note on Monday, July 6th. Zacks Research cut shares of Merck & Co., Inc. from a “hold” rating to a “strong sell” rating in a report on Monday, October 19th. Finally, Citigroup raised their price objective on shares of Merck & Co., Inc. from $125.00 to $145.00 and gave the company a “neutral” rating in a research report on Monday, October 12th. Seventeen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.08.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $149.75 on Monday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The firm has a market capitalization of $369.46 billion, a P/E ratio of 154.38, a PEG ratio of 6.48 and a beta of 0.21. The company’s fifty day moving average is $146.90 and its two-hundred day moving average is $126.69.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.56%. The business had revenue of $18.09 billion during the quarter, compared to the consensus estimate of $17.33 billion. During the same quarter last year, the firm posted $2.58 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. Analysts forecast that Merck & Co., Inc. will post 2.81 EPS for the current fiscal year.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Insider Activity

In other Merck & Co., Inc. news, EVP David Maraldo sold 18,706 shares of the company’s stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the transaction, the executive vice president directly owned 18,212 shares in the company, valued at approximately $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This trade represents a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 228,238 shares of company stock valued at $29,977,783 in the last quarter. Insiders own 0.17% of the company’s stock.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.